Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 7Lung Neoplasms 6Carcinoma, Non-Small-Cell Lung 5Ovarian Neoplasms 4Multiple Myeloma 4Lymphoma 4Endometrial Neoplasms 3Carcinoma, Hepatocellular 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2Neoplasm Metastasis 2Hereditary Sensory and Autonomic Neuropathies 2Hematologic Neoplasms 2Glioblastoma 2Fallopian Tube Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Renal Cell 2Advanced Nonhematologic Malignancies 2Waldenstrom Macroglobulinemia 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Somatostatinoma 1Sarcoma, Synovial 1Sarcoma 1Recurrent Malignant Solid Neoplasm 1Recurrent Lung Squamous Cell Carcinoma 1Recurrence 1

Interventions

Cyclophosphamide 65Peripheral Blood Stem Cell Transplantation 37fludarabine phosphate 36Doxorubicin 31Etoposide 30Vincristine 29Whole-Body Irradiation 28Rituximab 26Prednisone 26Brentuximab Vedotin 26Mycophenolic Acid 25Filgrastim 22Cyclosporine 22Methotrexate 20Busulfan 19Cytarabine 18Radiotherapy 17Antilymphocyte Serum 16Tacrolimus 15Melphalan 15Carboplatin 14Ifosfamide 13Bortezomib 13Methylprednisolone 12Gemcitabine 11Flow Cytometry 10Lenalidomide 9Dexamethasone 9romidepsin 8Vorinostat 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Large-Cell, Anaplastic × sapanisertib × Clear all
NCT03205891 2018-01-17

Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas

M.D. Anderson Cancer Center

Phase 1 Withdrawn
Lymphoid

Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡